The board of directors of AbbVie (NYSE:ABBV), a biopharmaceutical company, declared on Thursday its quarterly dividend of USD0.96 per share of its stock.
This 35% higher cash dividend is due on 15 May 2018 to stockholders of record at the close of business on 13 April 2018.
Since the company's inception in 2013, AbbVie has increased its dividend by 140 percent.
In addition, the company has approved a new USD10bn stock repurchase programme in open market or private transactions, has no time limit and may be discontinued at any time. The purchases may be made from time to time in management's discretion.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government